Læknaneminn - 01.04.2022, Page 27

25
Höfuðverkur, uppköst og
meðvitundarskerðing hjá 66 ára konu
Heimildaskrá
1. Chuzi S, Stein BL. Essential thrombocythemia: a review of
the clinical features, diagnostic challenges, and treatment
modalities in the era of molecular discovery. Leuk Lymphoma.
2017;58(12):2786­98.
2. Quadros AS, Cambruzzi E, Sebben J, David RB, Abelin A, Welter
D, et al. Red versus white thrombi in patients with ST­elevation
myocardial infarction undergoing primary percutaneous
coronary intervention: clinical and angiographic outcomes. Am.
Heart J. 2012;164(4):553­60.
3. Mora B, Passamonti F. Developments in diagnosis and
treatment of essential thrombocythemia. Expert Rev Hematol.
2019;12(3):159­71.
4. Accurso V, Santoro M, Mancuso S, Napolitano M, Carlisi M,
Mattana M, et al. The Essential Thrombocythemia in 2020:
What We Know and Where We Still Have to Dig Deep. Clinical
Medicine Insights: Blood Disorders. 2020;13:2634853520978210.
5. Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC,
Hanson C, et al. Validation of the revised international
prognostic score of thrombosis for essential thrombocythemia
(IPSET­thrombosis) in 585 Mayo clinic patients. Am. J. Hematol.
2016;91(4):390­4.
6. Winkler A, True D. Giant Cell Arteritis: 2018 Review. Mo Med.
2018;115(5):468­70.
7. Lincoff NS, Erlich PD, Brass LS. Thrombocytosis in temporal
arteritis rising platelet counts: a red flag for giant cell arteritis. J
Neuroophthalmol. 2000;20(2):67­72.
8. Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and
anticoagulant therapy in patients with giant cell arteritis.
Arthritis Rheum. 2006;54(10):3306­9.
9. Narváez J, Bernad B, Gómez­Vaquero C, García­Gómez C, Roig­
Vilaseca D, Juanola X, et al. Impact of antiplatelet therapy
in the development of severe ischemic complications and in
the outcome of patients with giant cell arteritis. Clin Exp
Rheumatol. 2008;26(3 Suppl 49):S57­62.
10. Elfarsson A, Guðbjörnsson B, Stefánsson E. Risafrumuæðabólga:
tvö sjúkratilfelli með skyndiblindu. Læknablaðið 2010;96(3):185­
9.
11. Majoor CJ, Sneeboer MM, de Kievit A, Meijers JC, van der Poll T,
Lutter R, et al. The influence of corticosteroids on hemostasis in
healthy subjects. J Thromb Haemost. 2016;14(4):716­23.
12. Soler EP, Ruiz VC. Epidemiology and risk factors of cerebral
ischemia and ischemic heart diseases: similarities and
differences. Curr Cardiol Rev. 2010;6(3):138­49.
13. Kato Y, Hayashi T, Sehara Y, Deguchi I, Fukuoka T, Maruyama H,
et al. Ischemic stroke with essential thrombocythemia: a case
series. J Stroke Cerebrovasc Dis. 2015;24(4):890­3.
14. Michiels JJ, van Genderen PJ, Lindemans J, van Vliet HH.
Erythromelalgic, thrombotic and hemorrhagic manifestations
in 50 cases of thrombocythemia. Leuk Lymphoma. 1996;22 Suppl
1:47­56.
15. Kumagai N, Mitsutake R, Miura S­i, Kawamura A, Takamiya Y,
Nishikawa H, et al. Acute coronary syndrome associated with
essential thrombocythemia. J. Cardiol. 2009;54(3):485­9.
16. Okayasu N, Murata M, Ueda A, Su K­M, Sada T, Ito T, et al.
Primary thrombocythemia and myocardial infarction in a
26­year­old woman with normal coronary arteriogram. Jpn.
Heart J. 1981;22(3):439­45.
17. Saffitz JE, Phillips ER, Temesy­Armos PN, Roberts WC.
Thrombocytosis and fatal coronary heart disease. Am. J.
Cardiol. 1983;52(5):651­2.
18. Wang L, Mao X, Zheng J, Gu X, Yang J. A case of simultaneous
acute cardio­cerebral infarction in a woman with essential
thrombocythemia. J. Int. Med. Res. 2019;47(9):4557­61.
19. Papo M, Delaval L, de BOYSSON H, Viallard J, Foucher A,
Humbert S, Duffau P, Contis A, Agard C, Bachmeyer C, Gombert
B, Guillevin L, Samson M, Terrier B. Giant­Cell Arteritis
Associated with Myeloproliferative Neoplasms: A Retrospective
Case–Control Study [abstract]. Arthritis Rheumatol. 2019;71
(suppl 10).
20. Montalto M, Biolato M, Gallo A, Racco S, Marrone G, Manna
R, et al. Severe giant cell arteritis associated with essential
thrombocythaemia. Int. J. Immunopathol. Pharmacol.
2010;23(4):1271­4.